Clotrimazole-d5
(Synonyms: 克霉唑 d5) 目录号 : GC47109
An internal standard for the quantification of clotrimazole
Cas No.:1185076-41-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Clotrimazole-d5 is intended for use as an internal standard for the quantification of clotrimazole by GC- or LC-MS. Clotrimazole is an imidazole antifungal agent.1 It is active against a variety of fungi, including C. albicans, A. fumigatus, S. cerevisiae, C. neoformans, T. mentagrophytes, and M. canis (MICs = <0.05-3.13 µg/ml).2 It inhibits the voltage-gated potassium channel Kv1.3 and the intermediate conductance calcium-activated potassium channel (IKCa1/KCa3.1; IC50s = 6 and 0.07 µM, respectively) and decreases proliferation of HaCaT keratinocytes (EC50 = 15 µM).3 Topical application of clotrimazole (1%) reduces oxazolone-induced ear swelling in an oxazolone-sensitized mouse model of delayed-type hypersensitivity. Clotrimazole (10 µM) also inhibits proliferation of A549 lung, HT-29 colon, and MM-RU melanoma cancer cells.4 Formulations containing clotrimazole have been used in the treatment of fungal skin infections.
1.Burgess, M.A., and Bodey, G.P.Clotrimazole (Bay b 5097): In vitro and clinical pharmacological studiesAntimicrob. Agents Chemother.2(6)423-426(1972) 2.Shadomy, S.In vitro antifungal activity of clotrimazole (Bay b 5097)Infect. Immun.4(2)143-148(1971) 3.Pegoraro, S., Lang, M., Dreker, T., et al.Inhibitors of potassium channels Kv1.3 and IK-1 as immunosuppressantsBioorg. Med. Chem. Lett.19(8)2299-2304(2009) 4.Benzaquen, L.R., Brugnara, C., Byers, H.R., et al.Clotrimazole inhibits cell proliferation in vitro and in vivoNat. Med.1(6)534-540(1995)
| Cas No. | 1185076-41-8 | SDF | |
| 别名 | 克霉唑 d5 | ||
| Canonical SMILES | ClC1=CC=CC=C1C(C2=CC=CC=C2)(N3C=CN=C3)C4=C([2H])C([2H])=C([2H])C([2H])=C4[2H] | ||
| 分子式 | C22H12ClD5N2 | 分子量 | 349.9 |
| 溶解度 | Chloroform: slightly soluble,Methanol: slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.858 mL | 14.2898 mL | 28.5796 mL |
| 5 mM | 0.5716 mL | 2.858 mL | 5.7159 mL |
| 10 mM | 0.2858 mL | 1.429 mL | 2.858 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。